SCHEMBL3059624

SCHEMBL3059624

O=C1C=CC(=O)C(CC(=O)O)=C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.48
MAOB P27338 4/20 0.48
ACHE P22303 2/20 0.42
BACE1 P56817 1/20 0.42
ALDH1A1 P00352 2/20 0.36
RECQL P46063 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36
KMT2A Q03164 1/20 0.36
AKR1B1 P15121 3/20 0.34
HSD17B3 P37058 1/20 0.32
CA2 P00918 1/20 0.32
CAMK2A Q9UQM7 1/20 0.32
ERBB2 P04626 1/20 0.32
PTGS2 P35354 1/20 0.31
BCHE P06276 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28973045 0.78 ACHE (0.48) MAOAMAOBACHEBACE1ALDH1A1
SCHEMBL11134940 0.77 MAOA (0.44) MAOAMAOBACHEBACE1ALDH1A1
Acetic Acid SCHEMBL27348090 0.74 ACHE (0.48) MAOAMAOBACHEBACE1ALDH1A1
SCHEMBL27996831 0.74 ACHE (0.44) MAOAMAOBACHEBACE1ALDH1A1
SCHEMBL1672539 0.74 ACHE (0.58) MAOAMAOBACHEBACE1MAPT
SCHEMBL5145016 0.73 MAOA (0.48) MAOAMAOBACHEBACE1ALDH1A1
SCHEMBL10766402 0.72 ACHE (0.61) MAOAMAOBACHEBACE1MAPT
SCHEMBL11492402 0.72 MAOA (0.44) MAOAMAOBACHEBACE1ALDH1A1
SCHEMBL7915011 0.72 ACHE (0.61) MAOAMAOBACHEBACE1ALDH1A1
SCHEMBL15071872 0.72 MAOA (0.64) MAOAMAOBACHEBACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0460996-B1 Keratinic fibres dyeing process with an aminoindol associated with a quinone derivative OREAL (FR) 1994-09-14 EP claimed
US-5180400-A METHOD FOR DYEING KERATINOUS FIBRES USING AN AMINOINDOLE IN COMBINATION WITH A QUINONE DERIVATIVE L'OREAL (FR) 1993-01-19 US claimed
EP-0460996-A1 Keratinic fibres dyeing process with an aminoindol associated with a quinone derivative L'OREAL (FR) 1991-12-11 EP claimed
EP-0376776-A2 Process for dyeing keratinous fibres with hydroxyindole associated with quinone and 1,4-benzoquinone L'OREAL (FR) 1990-07-04 EP claimed
CN-1043177-A Carry out the method for dyeing keratinous fibres and new 1,4-benzoquinones with oxyindole and quinone derivative OREAL (FR) 1990-06-20 CN claimed
US-10695342-B2 Methods and compositions for preventing opioid abuse ALBANY MOLECULAR RESEARCH, INC. (US) 2020-06-30 US disclosed
US-20170157116-A1 METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE CURIA BUFFALO R&D, LLC 2017-06-08 US disclosed
EP-2189468-B1 METHOD FOR MODIFICATION OF NUCLEOTIDES IN NUCLEIC ACID, AND NUCLEIC ACID HAVING MODIFIED NUCLEOTIDE THEREIN KEK HIGH ENERGY ACCELERATOR (JP) 2014-12-31 EP disclosed
US-8815539-B1 Methods for producing melanin and inorganic fertilizer from fermentation leachates River Road Research, Inc. (US) 2014-08-26 US disclosed
US-8492536-B2 Method for modifying nucleic acid bases, and nucleic acid base-modified product INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTE OF NATURAL SCIENCES (JP) 2013-07-23 US disclosed
US-20100222563-A1 METHOD FOR MODIFICATION OF NUCLEOTIDES IN NUCLEIC ACID, AND NUCLEIC ACID HAVING MODIFIED NUCLEOTIDE THEREIN INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTE OF NATURAL SCIENCES (JP) 2010-09-02 US disclosed
EP-2189468-A1 METHOD FOR MODIFICATION OF NUCLEOTIDES IN NUCLEIC ACID, AND NUCLEIC ACID HAVING MODIFIED NUCLEOTIDE THEREIN Inter-University Research Institute Corporation National Institutes of Natural Sciences (JP) 2010-05-26 EP disclosed
EP-0460996-B1 Keratinic fibres dyeing process with an aminoindol associated with a quinone derivative OREAL (FR) 1994-09-14 EP disclosed
EP-0603322-A1 DYEING COMPOSITION BASED ON HYDROXYINDOLINE DERIVATIVES. OREAL (FR) 1994-06-29 EP disclosed
WO-1993005018-A1 DYEING COMPOSITION BASED ON HYDROXYINDOLINE DERIVATIVES L'OREAL (FR) 1993-03-18 WO disclosed
US-5180400-A METHOD FOR DYEING KERATINOUS FIBRES USING AN AMINOINDOLE IN COMBINATION WITH A QUINONE DERIVATIVE L'OREAL (FR) 1993-01-19 US disclosed
EP-0376776-B1 PROCESS FOR DYEING KERATINOUS FIBRES WITH HYDROXYINDOLE ASSOCIATED WITH QUINONE AND 1,4-BENZOQUINONE L'OREAL (FR) 1992-09-23 EP disclosed
EP-0460996-A1 Keratinic fibres dyeing process with an aminoindol associated with a quinone derivative L'OREAL (FR) 1991-12-11 EP disclosed
US-5053053-A PROCESS FOR DYEING KERATINOUS FIBRES WITH A HYDROXYINDOLE IN COMBINATION WITH A QUINONE DERIVATIVE; AND NOVEL 1,4-BENZOQUINONES L'OREAL (FR) 1991-10-01 US disclosed
EP-0376776-A2 Process for dyeing keratinous fibres with hydroxyindole associated with quinone and 1,4-benzoquinone L'OREAL (FR) 1990-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10695342-B2 Methods and compositions for preventing opioid abuse OPRM1, OPRK1, OPRD1 MAOA 25/4885MAOB 22/4885ACHE 9/4885
US-20100222563-A1 METHOD FOR MODIFICATION OF NUCLEOTIDES IN NUCLEIC ACID, AND NUCLEIC ACID HAVING MODIFIED NUCLEOTIDE THEREIN NSUN2, ADAR, NT5C3B MAOA 3274/4885MAOB 2438/4885ACHE 4541/4885
US-20170157116-A1 METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE OPRM1, OPRK1, OPRD1 MAOA 25/4885MAOB 22/4885ACHE 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.